Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Serious Fraud Office Investigation

28th May 2014 07:00

RNS Number : 1700I
GlaxoSmithKline PLC
27 May 2014
 

 

Issued: 27 May 2014, London UK - LSE announcement

 

Serious Fraud Office Investigation

 

 

GlaxoSmithKline plc (LSE/NYSE: GSK) has today been informed by the UK's Serious Fraud Office (SFO) that it has opened a formal criminal investigation into the Group's commercial practices.

GSK is committed to operating its business to the highest ethical standards and will continue to cooperate fully with the SFO.

 

 

V A Whyte

Company Secretary

27 May 2014

 

 

GSK - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

 

 

GSK enquiries:

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)

Simon Steel

+44 (0) 20 8047 5502

(London)

US Media enquiries:

Stephen Rea

+1 215 751 4394

(Philadelphia)

Analyst/Investor enquiries:

Ziba Shamsi

+44 (0) 20 8047 5543

(London)

Kirsty Collins (SRI & CG)

+44 (0) 20 8047 5534

(London)

Tom Curry

+ 1 215 751 5419

(Philadelphia)

Gary Davies

+44 (0) 20 8047 5503

(London)

James Dodwell

+44 (0) 20 8047 2406

(London)

Jeff McLaughlin

+1 215 751 7002

(Philadelphia)

Lucy Singah

+44 (0) 20 8047 2248

(London)

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSEUFWWFLSELI

Related Shares:

Glaxosmithkline
FTSE 100 Latest
Value8,632.33
Change89.77